Cybin Announces Promising Results from Feasibility Study Measuring Psychedelic Effects on the Brain
Psychedelic therapy is gaining ground in the psychiatric and medical community. After what was essentially a ban on scientific study of hallucinogenic compounds for over three decades, new data are […]
How Does Ketamine Affect the Brain Over Time? Kernel Founder Tests his Invention
Kernel, a non-invasive neuroimaging company, and Cybin Inc. (NYSE American: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” have announced results from an innovative study involving ketamine and […]
Significant Breakthroughs in Psychedelic Medicine are Happening at Cybin
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, recently announced that the U.S. Food and Drug Administration (“FDA”) has authorized an Investigational New […]
Cybin Inc. Partners with Kernel’s Flow To Quantify Brain Activity During Therapy
According to The World Health Organization (WHO), one in four people in the world will be affected by mental or neurological disorders at some point in their lives. The COVID-19 […]
Cybin Advances Psilocybin as Treatment for Depression and Addiction
A biotechnology company focusing on psilocybin (found in several “psychedelic” mushrooms) recently announced significant advancements in treatment for depression and addiction. Cybin is a Canadian biotechnology company focusing on progressing […]